^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET wild-type

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase. (PubMed, J Med Chem)
    Importantly, in PK/PD studies, 39 exhibited a differentiated and favorable in vivo profile compared to the corresponding tyrosine kinase inhibitor (TKI), compound 3. Robust and sustained degradation of total-RET (tRET) protein and inhibition of phospho-RET (pRET) signaling were observed in TPC-1 xenograft tumors driven by RET and the RET/G810R mutant following a single dose of LDD 39 at 15 and 75 mg/kg, respectively.
    Journal
    |
    RET (Ret Proto-Oncogene) • CRBN (Cereblon)
    |
    RET mutation • RET G810R • RET V804M • RET V804* • RET wild-type
    8ms
    Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics. (PubMed, Elife)
    In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.
    Journal
    |
    RET (Ret Proto-Oncogene) • TMEM127 (Transmembrane Protein 127)
    |
    RET wild-type
    8ms
    Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. (PubMed, J Endocr Soc)
    When comparing RET M918T to RET indels there was no significant difference in time to DMD, DSS, or OS between the groups. Somatic RET mutations do not portend compromised DSS or OS in a cohort of sMTC patients who underwent clinically motivated NGS.
    Journal • Next-generation sequencing
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation • RAS wild-type • RET M918T • RET wild-type
    8ms
    Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy. (PubMed, J Am Coll Surg)
    We identified molecular alterations and immune-related features that distinguish wtRET from mutRET MTC. While RET mutation drives MTC in the absence of other alterations, we showed that wtRET MTC frequently harbors MAPK pathway mutations. These findings may indicate a potential basis for MAPK-targeted therapy, possibly in combination with oncology immune-oncology agents for selected patients with wtRET MTC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • RET (Ret Proto-Oncogene) • STK11 (Serine/threonine kinase 11) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1)
    |
    PD-L1 expression • KRAS mutation • TMB-H • BRAF mutation • STK11 mutation • NF1 mutation • RET mutation • VHL mutation • HRAS mutation • RET wild-type
    |
    Retevmo (selpercatinib)
    11ms
    Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting. (PubMed, JCO Precis Oncol)
    These data suggest that RET fusions represent a negative prognostic factor in patients with metastatic solid tumors and highlight the need for wider genomic testing and use of RET-specific TKIs that could improve patient outcomes. Our study also highlights the value of real-world data when studying rare cancers or cancers with rare genomic alterations.
    Journal • Real-world evidence • Real-world • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET positive • RET wild-type
    1year
    Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts. (PubMed, Int Immunopharmacol)
    RET mutation may be a predictive biomarker of enhanced response to ICIs therapy. Extensive investigation of the underlying molecular mechanisms and prospective studies are needed in the future.
    Review • Journal • IO biomarker
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation • RET wild-type
    1year
    Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. (PubMed, JCO Precis Oncol)
    Amplification of wild-type RET represents a novel, targetable molecular subset of cancer.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET rearrangement • RET amplification • RET wild-type
    |
    Retevmo (selpercatinib)